$TARA
Protara Therapeutics, Inc.

2020 Q1 Form 10-K Financial Statement

#000117184320001860 Filed on March 20, 2020

View on sec.gov

Income Statement

Concept 2020 Q1 2019 Q4 2019
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.090M $1.580M $8.820M
YoY Change 173.75% -41.91% -7.35%
% of Gross Profit
Research & Development $3.060M $60.00K $6.438M
YoY Change -24.41% -97.74% -45.66%
% of Gross Profit
Depreciation & Amortization $50.00K $0.00 $279.0K
YoY Change -71.26% -100.0% 142.61%
% of Gross Profit
Operating Expenses $10.16M $1.640M $15.25M
YoY Change 53.08% -69.55% -28.63%
Operating Profit -$15.25M
YoY Change -28.63%
Interest Expense $100.0K $30.00K $260.0K
YoY Change -9.09% -76.92% -40.91%
% of Operating Profit
Other Income/Expense, Net $0.00 $262.0K
YoY Change -59.25%
Pretax Income -$10.06M -$1.610M -$14.97M
YoY Change 54.06% -69.39% -16.19%
Income Tax
% Of Pretax Income
Net Earnings -$10.06M -$1.610M -$14.99M
YoY Change 54.03% -69.39% -27.68%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$1.809M -$3.038M -$29.98M
COMMON SHARES
Basic Shares Outstanding 5.843M 19.59M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q1 2019 Q4 2019
SHORT-TERM ASSETS
Cash & Short-Term Investments $36.10M $6.200M $6.200M
YoY Change 114.88% -71.69% -71.69%
Cash & Equivalents $36.10M $6.181M $6.200M
Short-Term Investments $0.00 $0.00
Other Short-Term Assets $3.700M $800.0K $800.0K
YoY Change 236.36% -42.86% -42.86%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $39.70M $6.975M $7.000M
YoY Change 121.38% -69.98% -69.83%
LONG-TERM ASSETS
Property, Plant & Equipment $1.000M $0.00
YoY Change 852.38% -100.0%
Goodwill $29.50M
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $0.00
YoY Change
Total Long-Term Assets $30.40M $0.00 $0.00
YoY Change 23837.01% -100.0% -100.0%
TOTAL ASSETS
Total Short-Term Assets $39.70M $6.975M $7.000M
Total Long-Term Assets $30.40M $0.00 $0.00
Total Assets $70.10M $6.975M $7.000M
YoY Change 288.15% -70.35% -70.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.600M $263.0K $300.0K
YoY Change 55.13% -40.36% -25.0%
Accrued Expenses $1.000M $320.0K $300.0K
YoY Change -35.86% -87.86% -88.46%
Deferred Revenue
YoY Change
Short-Term Debt $1.300M $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.000M $583.0K $600.0K
YoY Change 48.37% -81.06% -80.65%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $400.0K
YoY Change
Total Long-Term Liabilities $400.0K $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $5.000M $583.0K $600.0K
Total Long-Term Liabilities $400.0K $0.00 $0.00
Total Liabilities $5.400M $583.0K $600.0K
YoY Change 60.24% -81.06% -80.65%
SHAREHOLDERS EQUITY
Retained Earnings -$225.5M
YoY Change 7.12%
Common Stock $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $64.70M $6.392M $6.400M
YoY Change
Total Liabilities & Shareholders Equity $70.10M $6.975M $7.000M
YoY Change 288.15% -70.35% -70.21%

Cashflow Statement

Concept 2020 Q1 2019 Q4 2019
OPERATING ACTIVITIES
Net Income -$10.06M -$1.610M -$14.99M
YoY Change 54.03% -69.39% -27.68%
Depreciation, Depletion And Amortization $50.00K $0.00 $279.0K
YoY Change -71.26% -100.0% 142.61%
Cash From Operating Activities -$7.150M -$3.140M -$15.65M
YoY Change 40.42% -27.15% -32.66%
INVESTING ACTIVITIES
Capital Expenditures -$250.0K $0.00 $16.00K
YoY Change -1662.5% -100.0% -86.55%
Acquisitions
YoY Change
Other Investing Activities $3.720M $0.00 $2.500M
YoY Change 48.8% -100.0% -86.52%
Cash From Investing Activities $3.470M $0.00 $2.484M
YoY Change 39.69% -100.0% -86.52%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 39.23M 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -7.150M -3.140M -15.65M
Cash From Investing Activities 3.470M 0.000 2.484M
Cash From Financing Activities 39.23M 0.000
Net Change In Cash 35.55M -3.140M -13.16M
YoY Change -1463.11% -370.69% 631.63%
FREE CASH FLOW
Cash From Operating Activities -$7.150M -$3.140M -$15.65M
Capital Expenditures -$250.0K $0.00 $16.00K
Free Cash Flow -$6.900M -$3.140M -$15.66M
YoY Change 35.08% -25.42% -32.93%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
CY2019 dei Document Period End Date
DocumentPeriodEndDate
2019-12-31
CY2019 dei Amendment Flag
AmendmentFlag
false
CY2019 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2019 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2019 dei Document Type
DocumentType
10-K
CY2019 dei Entity Central Index Key
EntityCentralIndexKey
0001359931
CY2020Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
5843203
CY2019 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2019 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2019 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2019 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2019Q2 dei Entity Public Float
EntityPublicFloat
5800000
CY2019 dei Entity Registrant Name
EntityRegistrantName
ArTara Therapeutics, Inc.
CY2019 dei Entity Shell Company
EntityShellCompany
false
CY2019 dei Entity Small Business
EntitySmallBusiness
true
CY2019 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2019 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2019 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2019 dei Trading Symbol
TradingSymbol
tara
CY2019Q4 tara Contracted Service Costs
ContractedServiceCosts
9000
CY2018Q4 tara Contracted Service Costs
ContractedServiceCosts
968000
CY2019 tara Effective Income Tax Rate Reconciliation Nondeductible Expense Excluding Stock Compensation
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcludingStockCompensation
1000
CY2018 tara Effective Income Tax Rate Reconciliation Nondeductible Expense Excluding Stock Compensation
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcludingStockCompensation
6000
CY2019 tara Effective Income Tax Rate Reconciliation Writeoff Of Deferred Tax Asset Amount
EffectiveIncomeTaxRateReconciliationWriteoffOfDeferredTaxAssetAmount
2048000
CY2018 tara Effective Income Tax Rate Reconciliation Writeoff Of Deferred Tax Asset Amount
EffectiveIncomeTaxRateReconciliationWriteoffOfDeferredTaxAssetAmount
CY2019 tara Foreign Currency Remeasurement Gain Loss
ForeignCurrencyRemeasurementGainLoss
CY2018 tara Foreign Currency Remeasurement Gain Loss
ForeignCurrencyRemeasurementGainLoss
25000
CY2019 tara Income Tax Reconciliation State Income Taxes Net Of Federal Benefit
IncomeTaxReconciliationStateIncomeTaxesNetOfFederalBenefit
-930000
CY2018 tara Income Tax Reconciliation State Income Taxes Net Of Federal Benefit
IncomeTaxReconciliationStateIncomeTaxesNetOfFederalBenefit
-958000
CY2019 tara Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-200000
CY2018 tara Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
CY2019 tara Increase Decrease In Operating Lease Rightofuse Assets
IncreaseDecreaseInOperatingLeaseRightofuseAssets
-200000
CY2018 tara Increase Decrease In Operating Lease Rightofuse Assets
IncreaseDecreaseInOperatingLeaseRightofuseAssets
CY2019Q4 tara Operating Loss Carryforwards Net Indefinite Lived
OperatingLossCarryforwardsNetIndefiniteLived
30600000
CY2019 tara Proceeds From Issuance Of Common Stock Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
CY2018 tara Proceeds From Issuance Of Common Stock Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
2853000
CY2019 tara Proceeds From Issuance Of Common Stock Under Espp
ProceedsFromIssuanceOfCommonStockUnderESPP
CY2018 tara Proceeds From Issuance Of Common Stock Under Espp
ProceedsFromIssuanceOfCommonStockUnderESPP
132000
CY2002Q1 tara Royalty Payment Percentage Of Net Sales
RoyaltyPaymentPercentageOfNetSales
0.025
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
263000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
441000
CY2019 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
4000
CY2018 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
51000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
320000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2637000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
307000
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
279000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
827000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
3000
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
5000
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
213388000
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
209385000
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3429000
CY2018Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
2496000
CY2018Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
CY2018Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
CY2019Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
943000
CY2018Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
2496000
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
943000
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3429000
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
476390
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
667750
CY2019Q4 us-gaap Assets
Assets
6975000
CY2018Q4 us-gaap Assets
Assets
23521000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
6975000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
23236000
CY2019Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
5841000
CY2018Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
20849000
CY2018Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
2496000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6181000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19371000
CY2019Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
6200000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
19393000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
21192000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
6231000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-13162000
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1799000
CY2019Q4 us-gaap Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
50000
CY2019Q4 us-gaap Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
50000
CY2018Q4 us-gaap Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
0
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
664961
CY2018Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
684871
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
557631
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
481091
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
557631
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
481091
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14994000
CY2018 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-20710000
CY2019 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Concentrations of Credit Risk and Off-Balance Sheet Risk</div></div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash, cash equivalents and short-term investments. The Company's cash and cash equivalents are held in accounts with financial institutions that management believes are creditworthy. The Company's investment policy includes guidelines on the quality of the institutions and financial instruments and defines allowable investments that the Company believes minimizes the exposure to concentration of credit risk. These amounts at times <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>exceed federally insured limits. The Company has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> experienced any credit losses in such accounts and does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> believe it is exposed to any significant credit risk on these funds. The Company has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> financial instruments with off-balance sheet risk of loss.</div></div></div></div></div></div></div></div>
CY2019 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
CY2019 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2018 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2019Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
74000
CY2018Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
132000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
14810000
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
12358000
CY2019Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
CY2018Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
11090000
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
6742000
CY2019Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
59000
CY2018Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
169000
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards General Business
DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness
3587000
CY2018Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards General Business
DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness
3122000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1782000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
411000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
14810000
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-30.15
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-45.80
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
12358000
CY2019 us-gaap Depreciation
Depreciation
279000
CY2018 us-gaap Depreciation
Depreciation
115000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-27000
CY2019 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
CY2018 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
22000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4000
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1390000
CY2019Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
0
CY2018Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
4600000
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8816000
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9524000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-14965000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-17855000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-2874000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-14992000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-20729000
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2019 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
2449000
CY2018 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
5409000
CY2019 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
5000
CY2018 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
602000
CY2019 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-3148000
CY2018 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-4348000
CY2019 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
CY2018 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
325000
CY2019 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
40000
CY2018 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
430000
CY2019 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
465000
CY2018 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
1466000
CY2019 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2497000
CY2018 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-6162000
CY2019 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-17000
CY2018 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-49000
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-608000
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-141000
CY2019 us-gaap Investment Income Net
InvestmentIncomeNet
262000
CY2018 us-gaap Investment Income Net
InvestmentIncomeNet
436000
CY2019Q4 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
0
CY2018Q4 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
22000
CY2019Q4 us-gaap Liabilities
Liabilities
583000
CY2018Q4 us-gaap Liabilities
Liabilities
3078000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6975000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
23521000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
583000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3078000
CY2019Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2018Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2018Q4 us-gaap Loans Pledged As Collateral
LoansPledgedAsCollateral
22000
CY2017Q4 us-gaap Loans Pledged As Collateral
LoansPledgedAsCollateral
22000
CY2019Q4 us-gaap Loss Contingency New Claims Filed Number
LossContingencyNewClaimsFiledNumber
4
CY2019 us-gaap Nature Of Operations
NatureOfOperations
<div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; min-width: 700px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top"> <td style="width: 0.5in; font-size: 10pt; text-align: justify"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.</div></div></div></td> <td style="width: 0.25in; font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: justify"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-weight: bold;">Organization and Operations</div></div></td> </tr> </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">The Company</div></div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">&nbsp;</div></div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">ArTara Therapeutics, Inc (formerly Proteon Therapeutics, Inc., the &#x201c;Company&#x201d;) is a biopharmaceutical company that has historically focused on the development of novel, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div>-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular disease. The Company was formed in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 2001 </div>and incorporated on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 24, 2006.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 28, 2019, </div>the Company announced that its <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">second</div> Phase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div> trial, PATENCY-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,</div> for vonapanitase did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> meet its co-primary endpoints of fistula use for hemodialysis (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">p=0.328</div>) and secondary patency (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">p=0.932</div>). The PATENCY-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div> clinical trial was the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">second</div> of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> randomized, double-blind Phase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div> trials, comparing a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30</div> microgram dose of investigational vonapanitase to placebo in patients with chronic kidney disease, or CKD, undergoing creation of a radiocephalic fistula for hemodialysis. Following the release of top-line data from the PATENCY-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div> clinical trial of vonapanitase on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 28, 2019, </div>the Company began to evaluate its strategic alternatives focusing on enhancing stockholder value. On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 23, 2019, </div>the Company entered into a merger agreement with ArTara Subsidiary, Inc. (formerly ArTara Therapeutics, Inc. &#x201c;Private ArTara&#x201d;). As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2019, </div>the Company had discontinued substantially all its research and development activities, including a reduction in workforce. As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2019, </div>the Company had terminated all of its legacy Proteon Therapeutics, Inc. employees. The Company has recorded severance costs of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.9</div> million for the year ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2019. </div>The Company remains subject to a number of risks similar to other companies in the biotechnology industry, including compliance with government regulations, protection of proprietary technology, dependence on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div> parties and product liability.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Reverse Merger with Private ArTara</div></div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 9, 2020, </div>the Company and Private ArTara completed the merger and reorganization (the &#x201c;Merger&#x201d;) in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 23, 2019 (</div>the &#x201c;Merger Agreement&#x201d;), by and among the Company, Private ArTara and REM <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div> Acquisition, Inc., a wholly owned subsidiary of the Company (the &#x201c;Merger Sub&#x201d;), whereby Merger Sub merged with and into Private ArTara, with Private ArTara surviving as a wholly owned subsidiary of the Company.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 9, 2020, </div>in connection with, and prior to the completion of, the Merger, the Company effected a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div>-for-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">40</div> reverse stock split of its common stock, (the &#x201c;Reverse Stock Split&#x201d;), Private ArTara changed its name from &#x201c;ArTara Therapeutics, Inc.&#x201d; to &#x201c;ArTara Subsidiary, Inc.&#x201d;, and the Company changed its name from &#x201c;Proteon Therapeutics, Inc.&#x201d; to &#x201c;ArTara Therapeutics, Inc.&#x201d; All share and per share amounts presented in these financial statements have been adjusted to reflect the Reverse Stock Split.&nbsp;In addition, immediately following the closing of the Private Placements (defined below), all of the outstanding shares of the Company&#x2019;s Series A Preferred Stock were converted into shares of the Company&#x2019;s common stock. Shares of the Company&#x2019;s common stock commenced trading on The Nasdaq Capital Market under the new name and ticker symbol &#x201c;TARA&#x201d; as of market open on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 10, 2020.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under the terms of the Merger Agreement, the Company issued shares of its common stock (&#x201c;Common Stock&#x201d;) to Private ArTara&#x2019;s stockholders, at an exchange ratio of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.190756</div> shares of Common Stock, after taking into account the Reverse Stock Split, for each share of Private ArTara common stock outstanding immediately prior to the Merger. Proteon assumed all of the outstanding and unexercised stock options of Private ArTara, with such stock options now representing the right to purchase a number of shares of Common Stock equal to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.190756</div> multiplied by the number of shares of Private ArTara common stock previously represented by such Private ArTara stock options. The Company also assumed all of the unvested Private ArTara restricted stock awards, which were exchanged for a number of shares of Common Stock equal to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.190756</div> multiplied by the number of shares of Private ArTara common stock previously represented by such Private ArTara restricted stock awards and unvested to the same extent as such Private ArTara restricted stock awards and subject to the same restrictions as such Private ArTara restricted stock awards.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 9, 2020, </div>the Company completed certain private placements pursuant to a subscription agreement entered into on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 23, 2019. </div>On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 23, 2019, </div>the Company and Private ArTara entered into a subscription agreement (as amended on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> November 19, 2019, </div>the "Subscription Agreement") with certain institutional investors (the "Investors") pursuant to which, among other things, (i) the Company agreed to issue to certain Investors shares of Proteon Series <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div> Convertible Non-Voting Preferred Stock and/or Proteon common stock immediately following the Merger in a private placement transaction for an aggregate purchase price of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$40.5</div> million (the "Proteon Private Placement") and (ii) Private ArTara agreed to issue to an Investor (that is an existing investor in ArTara) shares of ArTara common stock (the "ArTara Private Placement Shares") immediately prior to the Merger in a private placement transaction for an aggregate purchase price of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.0</div> million (together with the Proteon Private Placement, the "Private Placements"). Immediately after the Proteon Private Placement, the Company converted all outstanding shares of Proteon's Series A Convertible Preferred Stock into shares of Proteon common stock (the "Series A Preferred Automatic Conversion"). On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 9, 2020, </div>the Company received approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$39.6</div> million, net of offering costs related to the Private Placements.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Merger was structured as a reverse merger and Private ArTara was determined to be the accounting acquirer based on the terms of the Merger Agreement. The Merger will be accounted for as a business combination as of the effective date of the Merger.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</div> <!-- Field: Page; Sequence: 80 --> <!-- Field: /Page --> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The financial information included in the financial statements is that of the Company prior to the Merger because the Merger was consummated after the period covered by these financial statements.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Liquidity </div></div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2019, </div>the Company had cash and cash equivalents of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$6.2</div> million. The Company had an accumulated deficit of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$225.5</div> million as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2019.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In connection with the Merger, the Company consummated the Private Placements, raising gross proceeds of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$42.5</div> million. The Company expects there will be <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> further material near term cash expenditures to fund the Company&#x2019;s vonapanitase clinical trials. From the date of the Merger, the activities of the Company will become those of Private ArTara.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company is in the business of developing biopharmaceuticals, has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> current or near term revenues. The Company is incurring substantial clinical and other costs in its drug development efforts. The Company expects it will need to raise additional capital in order to fully realize management&#x2019;s plans.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company believes that its current financial resources, as of the date of the issuance of these consolidated financial statements, are sufficient to fund its current <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">twelve</div> month operating budget, alleviating any substantial doubt raised by our historical operating results and satisfying our estimated liquidity needs for at least <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">twelve</div> months from the issuance of these consolidated financial statements.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">&nbsp;</div></div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">At-The-Market Equity Offering Program</div></div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> November 12, 2015, </div>the Company filed a shelf registration statement on Form S-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div> (the &#x201c;Registration Statement&#x201d;), and entered into a Sales Agreement with Cowen and Company, LLC (the &#x201c;Sales Agreement&#x201d;) to establish an at-the-market (&#x201c;ATM&#x201d;) equity offering program pursuant to which they are able, with the Company&#x2019;s authorization, to offer and sell up to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$40</div> million of the Company&#x2019;s Common Stock at prevailing market prices from time to time. The Registration Statement became effective on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 12, 2016. </div>The Company paid Cowen a commission equal to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3%</div> of the gross proceeds of the sales price of all shares sold through it as sales agent under the Sales Agreement. The offering costs were offset against proceeds from the sale of common stock under this agreement. The Company filed a prospectus supplement on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 16, 2017 </div>because the Company is currently subject to General Instruction <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">I.B.6</div> of Form S-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,</div> which limits the amounts that the Company <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>sell under the Registration Statement. The Company&#x2019;s ATM program was terminated effective as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 7, 2019, </div>when its new shelf registration statement on Form S-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,</div> File <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">333</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">228865,</div> was declared effective by the SEC. For the year ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018, </div>the Company sold <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,494,579</div> shares of Common Stock under the Sales Agreement for aggregate gross proceeds of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3.0</div> million. For the year ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018, </div>total offering costs of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$46,000,</div> were offset against the proceeds from the sale of common stock. The <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,494,579</div> shares of Common Stock sold under the ATM program during the year ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018 </div>were all sold on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 25, 2018 </div>to New Leaf Venture Partners LLC.</div></div>
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2985000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
2484000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
18427000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15646000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23233000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-14992000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-20729000
CY2019 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
262000
CY2018 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
643000
CY2019 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2019 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2019 us-gaap Operating Expenses
OperatingExpenses
15254000
CY2018 us-gaap Operating Expenses
OperatingExpenses
21372000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-15254000
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-21372000
us-gaap Operating Lease Expense
OperatingLeaseExpense
200000
CY2018 us-gaap Operating Lease Expense
OperatingLeaseExpense
300000
CY2019 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-2000
CY2018 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-1000
CY2018 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
19000
CY2019 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-2000
CY2019 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
CY2018 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
20000
CY2019 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
CY2018 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
207000
CY2019 us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
0
CY2018 us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
0
CY2019 us-gaap Payments For Restructuring
PaymentsForRestructuring
2854000
CY2019 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
CY2018 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
15443000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
16000
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
119000
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
744000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1369000
CY2019 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
2500000
CY2018 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
31990000
CY2019 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
CY2018 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
1999000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1090000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
263000
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6438000
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11848000
CY2019Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
50000
CY2018Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
CY2019Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
CY2018Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
22000
CY2019 us-gaap Restructuring Charges
RestructuringCharges
2854000
CY2018Q4 us-gaap Restructuring Reserve
RestructuringReserve
CY2019Q4 us-gaap Restructuring Reserve
RestructuringReserve
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-225462000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-210470000
CY2019 us-gaap Severance Costs1
SeveranceCosts1
2900000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
943000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
3429000
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.026
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0255
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.896
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.935
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
111
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
218.40
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
63951
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
80431
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
29563
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
51040
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
80
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
104.32
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
404000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
114931
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
111
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
204.76
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
218.40
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
111
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
218.40
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
34740000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
20443000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
6392000
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
260.40
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
124.40
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
106.32
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y36D
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y25D
CY2019Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P36D
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y146D
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P36D
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P36D
CY2019 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
CY2018 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
132000
CY2018 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2852000
CY2019Q4 us-gaap Tax Credit Carryforward Amount
TaxCreditCarryforwardAmount
3600000
CY2018Q4 us-gaap Tax Credit Carryforward Amount
TaxCreditCarryforwardAmount
3100000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
497275
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
452555

Files In Submission

Name View Source Status
0001171843-20-001860-index-headers.html Edgar Link pending
0001171843-20-001860-index.html Edgar Link pending
0001171843-20-001860.txt Edgar Link pending
0001171843-20-001860-xbrl.zip Edgar Link pending
exh_1025.htm Edgar Link pending
exh_1029.htm Edgar Link pending
exh_1030.htm Edgar Link pending
exh_1036.htm Edgar Link pending
exh_211.htm Edgar Link pending
exh_231.htm Edgar Link pending
exh_311.htm Edgar Link pending
exh_312.htm Edgar Link pending
exh_321.htm Edgar Link pending
exh_43.htm Edgar Link pending
f10k_031820p.htm Edgar Link pending
figure_1.jpg Edgar Link pending
figure_10.jpg Edgar Link pending
figure_2.jpg Edgar Link pending
figure_3.jpg Edgar Link pending
figure_4.jpg Edgar Link pending
figure_6.jpg Edgar Link pending
figure_7.jpg Edgar Link pending
figure_8.jpg Edgar Link pending
figure_9.jpg Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tara-20191231.xml Edgar Link completed
tara-20191231.xsd Edgar Link pending
tara-20191231_cal.xml Edgar Link unprocessable
tara-20191231_def.xml Edgar Link unprocessable
tara-20191231_lab.xml Edgar Link unprocessable
tara-20191231_pre.xml Edgar Link unprocessable